Grifols (GRFS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $6.15B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | ES | CEO | Jose Ignacio Abia Buenache |
| IPO Date | 2011-06-02 | CAGR | 14.02% |
| Employees | 23,833 | Website | www.grifols.com |
| Div. Yield | 7.43% | Payout Ratio | 31% |
| Buy Back Yield | 8.91% | Total Yield | 16.34% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| Enterprise Value | $13.11B | P/E Ratio | 8.35 |
| Forward P/E | 5.03 | PEG Ratio | — |
| P/S Ratio | 0.19 | P/B Ratio | 0.26 |
| P/CF Ratio | 1.32 | P/FCF Ratio | 1.81 |
| EPS | $0.87 | EPS Growth 1Y | 114.86% |
| EPS Growth 3Y | 191.17% | EPS Growth 5Y | -26.33% |
| Revenue Growth 1Y | 1.02% | Gross Margin | 0.38% |
| Operating Margin | 0.17% | Profit Margin | 0.06% |
| ROE | 0.08% | ROA | 0.02% |
| ROCE | 0.07% | Current Ratio | 2.47 |
| Quick Ratio | 0.85 | Cash Ratio | 0.33 |
| Debt/Equity | 1.77 | Interest Coverage | 2.04 |
| Altman Z Score | 1.01 | Piotroski Score | 6 |
Grifols (GRFS) valuation & financials
Grifols (GRFS) has a market capitalization of $6.15B and trades at a price-to-earnings ratio of 8.3. It operates in the Healthcare sector (Drug Manufacturers - General).
Grifols's revenue grew +1.0% over the last year.
Grifols's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $0.28.
Grifols (GRFS) — frequently asked questions
When does Grifols (GRFS) report earnings next?
Grifols is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $0.28.
What is Grifols's market cap?
Grifols (GRFS) has a market capitalization of $6.15B.
What is GRFS's P/E ratio?
Grifols trades at a price-to-earnings ratio of 8.3, with trailing twelve-month EPS of $0.87.
How fast is Grifols growing?
Grifols's revenue grew +1.0% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)